The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

NPM-ALK(+) T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK(+) ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and death frequently occur. Recently, selective targeting of ALK has em...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: George, Suraj Konnath, Vishwamitra, Deeksha, Manshouri, Roxsan, Shi, Ping, Amin, Hesham M.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2014
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4170597/
https://ncbi.nlm.nih.gov/pubmed/25026277
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires